Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
116 hedge funds and large institutions have $246M invested in Merrimack Pharmaceuticals, Inc. in 2017 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 31 increasing their positions, 41 reducing their positions, and 26 closing their positions.
15% less funds holding
Funds holding: 136 → 116 (-20)
24% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 41
41% less capital invested
Capital invested by funds: $415M → $246M (-$169M)
50% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 26
59% less call options, than puts
Call options by funds: $1.01M | Put options by funds: $2.47M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$36.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$4.01M |
| 3 |
Goldman Sachs
New York
|
+$3.51M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.41M |
| 5 |
AWCI
Alpine Woods Capital Investors
Purchase,
New York
|
+$2.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
-$37M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$37M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$20.4M |
| 4 |
ICP
Indus Capital Partners
New York
|
-$4.28M |
| 5 |
LIM
Lagoda Investment Management
New York
|
-$2.38M |
MACK Hedge Fund Activity: Q1 2017 in Review
116 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q1 2017, worth a combined $246M — down 41% from $415M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of MACK and 13 opened new positions — a net loss of 13 holders — while 41 trimmed existing stakes and 31 added.
The largest buyer was BlackRock, adding an estimated $36.7M. The largest seller was Westfield Capital Management, exiting entirely with an estimated $37M sold.
- 116 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q1 2017, down from 136 in Q4 2016.
- Funds reported $246M of Merrimack Pharmaceuticals, Inc. stock for Q1 2017, down 41% quarter-over-quarter.
- 13 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q1 2017 and 26 closed out, a net change of -13 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q1 2017 was BlackRock, an estimated $36.7M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q1 2017 was Westfield Capital Management, an estimated $37M sold.
Based on aggregated 13F filings for Q1 2017.